Establishing robust natural history datasets to better understand disease variability, progression, and key biomarkers for gene therapy targeting. – Utilizing real-world patient data to refine trial eligibility criteria, outcome measures, and regulatory submissions. – Strengthening evidence for efficacy and long-term benefits to support approvals, reimbursement, and patient access. (TBC)